ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2026
Increase in congenital syphilis in the European Union and European Economic Area, 2015 to 2024 - time to scale-up public health responses.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUNDCongenital syphilis (CS) is under routine surveillance in the European Union and European Economic Area (EU/EEA). In 2024, notifications reached their highest level in a decade, coinciding with rising syphilis among women.AIMWe describe CS cases in 2024, trends from 2015 to 2024, associations between CS rates and syphilis among women of reproductive age, and public health implications.METHODSConfirmed CS cases and syphilis notifications in 15-44-year-old women reported by EU/EEA countries between 2015 and 2024 were extracted from EpiPulse. For CS cases in 2024, we described key demographics and outcome (alive/deceased). Country-specific CS and syphilis rates per 100,000 were calculated using Eurostat denominators. We assessed associations between CS and syphilis in women using quasi-Poisson regression adjusting for population size and year.RESULTSIn 2024, 28 EU/EEA countries reported 140 confirmed CS cases, Bulgaria, Hungary and Portugal accounting for 62% (87/140). Most cases were diagnosed neonatally (86/99; 87%), and 11 of 58 were deceased. From 2015 to 2024, CS rates increased from 1.3 to 5.2 per 100,000 live births (23 countries) and syphilis rates among women aged 15-44 years from 1.9 to 5.3 per 100,000 (22 countries). Regression analyses showed significant positive associations between syphilis in women and CS rates in Germany and Hungary, whereas CS increases in Romania and Slovakia remained after adjustment for syphilis among women.CONCLUSIONThe CS increase highlights prevention gaps. Strengthened surveillance, national audits of antenatal screening pathways, and testing policies adapted to evolving epidemiology are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.